- Home
- ONFO vs PBM Comparison
ONFO vs PBM Comparison
Compare ONFO & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- PBM
- Stock Information
- Founded
- ONFO 2018
- PBM 1994
- Country
- ONFO United States
- PBM Canada
- Employees
- ONFO N/A
- PBM N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- PBM
- Sector
- ONFO Technology
- PBM
- Exchange
- ONFO Nasdaq
- PBM NYSE
- Market Cap
- ONFO 6.7M
- PBM 7.5M
- IPO Year
- ONFO 2022
- PBM N/A
- Fundamental
- Price
- ONFO $1.26
- PBM $1.79
- Analyst Decision
- ONFO
- PBM
- Analyst Count
- ONFO 0
- PBM 0
- Target Price
- ONFO N/A
- PBM N/A
- AVG Volume (30 Days)
- ONFO 158.2K
- PBM 5.4M
- Earning Date
- ONFO 11-15-2024
- PBM 02-02-2025
- Dividend Yield
- ONFO N/A
- PBM N/A
- EPS Growth
- ONFO N/A
- PBM N/A
- EPS
- ONFO N/A
- PBM N/A
- Revenue
- ONFO $6,590,171.00
- PBM N/A
- Revenue This Year
- ONFO $133.59
- PBM N/A
- Revenue Next Year
- ONFO N/A
- PBM N/A
- P/E Ratio
- ONFO N/A
- PBM N/A
- Revenue Growth
- ONFO 29.25
- PBM N/A
- 52 Week Low
- ONFO $0.39
- PBM $1.51
- 52 Week High
- ONFO $1.88
- PBM $593.25
- Technical
- Relative Strength Index (RSI)
- ONFO 44.75
- PBM 39.22
- Support Level
- ONFO $1.15
- PBM $1.61
- Resistance Level
- ONFO $1.39
- PBM $2.25
- Average True Range (ATR)
- ONFO 0.09
- PBM 0.22
- MACD
- ONFO -0.01
- PBM 0.06
- Stochastic Oscillator
- ONFO 36.67
- PBM 23.38
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.